LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

ABBV

193.18

+0.34%↑

MRK

117.82

-0.52%↓

Home・Aktien・Johnson and Johnson

Johnson and Johnson

Geschlossen

Branche Gesundheitswesen

164.37 -0.29

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

164.14

Max

164.71

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.4B 4.7B
Verkäufe	1.1B 22B
KGV Branchendurchschnitt	21.72 103.001
EPS	2.82
Gewinnspanne	20.873
Angestellte	131,900
EBITDA	2.1B 7.8B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+4.92 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	15. Okt. 2024
Nächste Dividendenausschüttung	10. Sept. 2024
Nächstes Ex-Dividendendatum	18. Nov. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	400B
Vorheriger Eröffnungskurs	164.66
Vorheriger Schlusskurs	164.37

Nachrichtenstimmung

By Acuity

41%

59%

90 / 365 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

164.13 / 164.61 Unterstützung & Widerstand

Johnson and Johnson Chart

Ähnliche Nachrichten

20. Aug. 2024, 12:16 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600 Million

20. Aug. 2024, 11:43 UTC

Top News

Johnson & Johnson's Rybrevant, Lazcluze Combo Gets FDA Approval for Type of Advanced Lung Cancer

17. Juli 2024, 14:14 UTC

Ergebnisse

Trending: Johnson & Johnson Beats 2Q Sales Guidance

4. Sept. 2024, 23:20 UTC

Top News

Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement -- Update

23. Aug. 2024, 20:54 UTC

Top News

J&J Takes Aim at Hospital Drug-Discount Program -- Update

23. Aug. 2024, 18:09 UTC

Top News

J&J Takes Aim At Hospital Drug-Discount Program -- WSJ

20. Aug. 2024, 12:41 UTC

Top News

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Gets FDA Approval for Treatment, Makes Acquisition of Up to $1.7 Billion -- Barrons.com

20. Aug. 2024, 12:01 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson to Buy V-Wave for Upfront Payment of $600M

20. Aug. 2024, 11:55 UTC

Akquisitionen, Fusionen, Übernahmen

J&J To Acquire V-Wave For Up To $1.7 Billion In Play For Heart Failure Device -- MarketWatch

20. Aug. 2024, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Expects the Transaction to Dilute Adjusted EPS by 24c in 2024 and 6c in 2025 >JNJ

20. Aug. 2024, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Transaction Is Expected to Close Before the End of 2024 >JNJ

20. Aug. 2024, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Will Join Johnson & Johnson as Part of Johnson & Johnson MedTech >JNJ

20. Aug. 2024, 11:31 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson Will Acquire V-Wave for an Upfront Payment of $600M With the Potential for Additional Regulatory and Comml Milestone Payments Up to $1.1B >JNJ

20. Aug. 2024, 11:30 UTC

Akquisitionen, Fusionen, Übernahmen

Johnson & Johnson To Acquire V-Wave >JNJ

20. Aug. 2024, 11:12 UTC

Top News

Johnson & Johnson Wins First FDA Approval For Chemotherapy-Free Lung Cancer Treatment -- MarketWatch

12. Aug. 2024, 14:30 UTC

Akquisitionen, Fusionen, Übernahmen

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12. Aug. 2024, 09:30 UTC

Top News

Akquisitionen, Fusionen, Übernahmen

Big Drugmakers Are Clinching Smaller Deals -- WSJ

29. Juli 2024, 10:30 UTC

Top News

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

17. Juli 2024, 11:24 UTC

Market Talk

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

J&J Lifts Sales View But Lowers Earnings Outlook -- Market Talk

17. Juli 2024, 10:43 UTC

Ergebnisse

Johnson & Johnson Earnings Top, But Dow Stock Falls On Lowered Guidance -- IBD

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson: MedTech Operational Sales Growth Expected to Accelerate in 2H >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson Cuts 2024 View To Adj EPS $9.97-Adj EPS $10.07 Vs Prior View $10.57-$10.72 >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson Backs 2024 Adjusted Operational Sales Growth View of 5.5%-6% >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson: 2Q MedTech Worldwide Operational Sales Growth Was Driven Primarily by Electrophysiology Products and Abiomed in Cardiovascular, and Wound Closure Products in General Surgery >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson Backs 2024 Sales $88.0B-$88.4B >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson Cuts 2024 Adjusted Operational EPS View to $10.00-$10.10 Vs Prior View $10.60-$10.75 >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson: 2Q Innovative Medicine Worldwide Operational Sales, Excluding Covid Vaccine, Grew 8.8% >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson Updating 2024 Guidance to Reflect Improved Performance and Impact for Recent Acquisitions of Shockwave Medical, Proteologix and NM26 Bispecific Antibody >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson Raises 2024 Operational Sales View to $89.2B-$89.6B Vs Prior View $88.7B-$89.1B >JNJ

17. Juli 2024, 10:20 UTC

Ergebnisse

Johnson & Johnson 2Q Worldwide MedTech Sales $7.96B >JNJ

Peer-Vergleich

Kursveränderung

Johnson and Johnson Prognose

Kursziel

By TipRanks

4.92% Vorteil

12-Monats-Prognose

Durchschnitt 172.46 USD 4.92%

Hoch 215 USD

Tief 150 USD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Johnson and Johnson – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

14 ratings

Buy

Halten

Sell

Basierend auf 14 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Johnson and Johnson – Dist abgegeben haben.

Technischer Score

By Trading Central

164.13 / 164.61Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Stimmung

By Acuity

90 / 365 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Johnson and Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women’s health and wound care markets. The Pharmaceutical segment is focused on six immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedic, surgery, and vision fields.